Moteur de recherche d’entreprises européennes
Financement de l’UE (4 495 438 €) : Système d’aide à la décision basé sur l’intelligence artificielle pour la stratification des risques et la détection précoce de l’insuffisance cardiaque dans les … Hor 01/06/2023 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Système d’aide à la décision basé sur l’intelligence artificielle pour la stratification des risques et la détection précoce de l’insuffisance cardiaque dans les soins primaires et secondaires
Heart failure (HF) is a pandemic currently affecting up to 15 million people in Europe. It is a complex clinical syndrome presenting with impaired heart function and is associated with poor quality of life for patients and high healthcare costs. There is a high clinical demand for novel artificial intelligence (AI) tools which will facilitate risk stratification, early diagnosis, and disease progression assessment in HF. Such tools are essential to allow prompt initiation of evidence-based prevention and treatment strategies which will improve patient quality of life, reduce morbidity and mortality and the HF burden on healthcare. STRATIFYHF aims to develop, validate and implement the first AI-based, decision support system (DSS) for risk stratification, early diagnosis, and disease progression assessment in HF to accommodate both primary and secondary care clinical needs. The DSS will integrate patient-specific demographic and clinical data using existing and novel technologies and establish AI-based tools for risk stratification and HF prediction using machine learning. Additionally, a mobile app will be developed to empower patients to better manage their condition, and health care professionals to make informed decision in selection of evidence-based HF prevention and treatment strategies. Our multidisciplinary consortium, including three small-to-medium enterprises (SMEs) and two stakeholder organisations, will be guided by medical advice and regulatory and health technology experts to deliver the DSS as a medical class 2b device, reaching TRL 8 by the end of the project. STARTIFYHF will change the way in which HF is diagnosed today and thereby improve the quality and length of patients’ lives and lead to efficient and sustainable healthcare systems by reducing the number of HF-related hospital admissions and unnecessary referrals from primary to secondary care in Europe and beyond.
| Coventry University | ? |
| Azienda Ospedaliero-Universitaria Careggi | 0,00 € |
| Azienda Unita' Sanitaria Locale Toscana Centro | 0,00 € |
| BCN Health Economics & Outcomes Research SL | 346 500 € |
| Gpcardio B.V. | 101 243 € |
| Idryma Technologias Kai Erevnas | 438 750 € |
| Institut ZA Kardiovaskularne Bolesti Vojvodine | 0,00 € |
| Istrazivacko Razvojni Centar ZA Bioinzenjering Bioirc d.o.o. | 892 500 € |
| Klinikum DER Universitaet Regensburg | 446 250 € |
| Medcon International B.V. | 43 132 € |
| Servicio Madrileno de Salud | 406 250 € |
| Udruzenje ZA Srcanu Slabost Srbije | 151 875 € |
| Universita Degli Studi Di Firenze | 436 250 € |
| Universitair Medisch Centrum Utrecht | 452 500 € |
| University OF Novi SAD, Faculty OF Medicine Novi SAD | 425 188 € |
| Univerza V Ljubljani | 355 000 € |
https://cordis.europa.eu/project/id/101080905
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Coventry University UNIVERSITY, Coventry, Royaume Uni.